Prospects for targeted therapy of gliomas

Vestnik Rossiiskoi Akademii Meditsinskikh Nauk

Volumn , Issue 4, 2009, Pages 30-42

  Chekhonin, V P ^a   Baklaushev, V P ^a   Yusubalieva, G M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84876827767     PISSN: 08696047     EISSN: 24143545     Source Type: Journal    
DOI: None     Document Type: Review

References (121)

1. Gupta T., Sarin R. Pootvprasaosi high-grade gliomas: evolving an evidence-based standard of care. Lancet Oncol. 2002;3:557-564.
2. Stewart L, A. Chemotherapy in adult high-grade glioma: A systematic review and meta-analysis of individual patient data from 12 randomized trials. Lancet 2002;359:1011-1018.
3. Zoluttky M. R. Current status of therapy of solid tumors: Brain tumor therapy. J. Nucl. Med. 2005;46(suppl.):151S-156S.
4. Chang C. H., Sharkey R. M., Rossi E. A. et al. Molecular advances in pretargeting radioimmunotherapy with bispecific antibodies. Mol. Cancer Ther. 2002;1:553-563.
5. Gold P., Freedman S. O. Demonstration of tumor specific antigens in human colonic carcinoma by immunological tolerance and absorption techniques. I. Exp. Med. 1965;121:439-462.
6. Bergstrand C. G., Czar B. Demonstration of a new protein fraction in serum from the human fetus. Scand. J. Clin. Lab. Invest. 1956;8:174-179.
7. Abelev G. I., Perova S. D., Khramkova N. I. et al. Embryonal serum alpha-globulin and its synthesis by transplantable mouse hepatomas. Biokhimiia 1963;28:625-634.
8. Parsons T. F., Pierce J. G. Biologically active covalently crosslinked glycoprotein hormones an the effects of modification of the COOH-terminal region of their alpha subunits. J. Biol. Chem. 1979;254:6010-6015.
9. Kdhler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256:495-497.
10. Kaminski M. S., Zelenetz A. D., Press O. W. et al. Pivotal study of iodine-131 tositumomab for chemotherapy-refractory lowgrade or transformed low-grade B-cell non-Hodgkin's lymphomas. J. Clin. Oncol. 2001;19:3918-3928.
11. Barbel J., Peltier P., Bardet S. et al. Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA x anti-DTPA-indium bispecific antibody. J. Nucl. Med. 1998;39:1172-1178.
12. 131I-labeled p97-specific Fab fragments in human melanoma as a basis for radiotherapy. J. Clin. Invest. 1983;72:2101-2114.
13. Epenetos A. A., Nimmon C. C., Arklie J. et al. Detection of human cancer in an animal model using radio-labelled tumour-associated monoclonal antibodies. Br. J. Cancer 1982;46:1-8.
14. Kosmas C., Kalofonos H. P., Hird V., EpenetosA. A. Monoclonal antibody targeting of ovarian carcinoma. Oncology 1998;55:435-446.
15. Brady L. W., Miyamoto C., Woo D. V. et al. Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: A phase II trial. Int. J. Radiat. Oncol. Biol. Phys. 1992;22:225-230.
16. Kumar S., Huber J., Pena L. A. et al. Characterization of functional nerve growth factor-receptors in a CNS glial cell line: Monoclonal antibody 217c recognizes the nerve growth factorreceptor on C6 glioma cells. J. Neurosci. Res. 1990;27:408-417.
17. Trojan J., Cloix J.-F., Ardourel M.-Y. Insulin-like growth factor type I biology and targeting in malignant gliomas. Neuroscience 2007;145:795-811.
18. Moosmayer D., Berndorff D., Chang C. H. Bispecific antibody pretargeting of tumor neovasculature for improved systemic radio-therapy of solid tumors. Clin. Cancer Res. 2006;12:5587-5595.
19. Spaeth N., Wyss M. T., Pahnke J. Radioimmunotherapy targeting the extra domain B of fibronectin in C6 rat gliomas: A preliminary study about the therapeutic efficacy of iodine-131-labeled SIP (L19). Nucl. Med. Bol. 2006;33:661-666.
20. 131 I-labeled antitenascin 81c6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: A phase II study. J. Nucl. Med. 2005;46:1042-1051.
21. 90Y radioimmunotherapy in a mouse xenograft model. J. Immunother. 1994;16:158.
22. Rtva P., Franceschi G., Rtva N. et al. Role of nuclear medicine in me treatment of malignant gliomas: The locoregional radioimmunotherapy approach. Eur. J. Nucl. Med. 2000;27:601-609.
23. Sampson J. H., Akabanl G., Friedman A. H. et al. Comparison of intratumoral bolus injection and convection-enhanced delivery of radiolabeled antitenascin monoclonal antibodies. Neurosurg. Focus 2006;20:E14.
24. 2 fragment delivery to tumor in patients with glioma: Comparison of intracarotid and intravenous administration. Cancer Res. 1990;50:4105-4110
25. Gupta B., Levchenko T. S., Mongayt D. A., Torchilin V. P. Monoclonal antibody 2C5-mediated binding of liposomes to brain tumor cells in vitro and in subcutaneous tumor model in vivo. J. Drug Target. 2005;13:337-343.
26. 131 I-chTNT-1/B mAb: Tumour necrosis therapy for malignant astrocytic glioma. Expert Opin. Biol. Ther. 2006;6:539-545.
27. Dams A. G., Richardson R. B., Bourne S. P. et al. Immunolocalisation of human brain tumors. In: Bleehan N. M., ed. Tumors of the brain. Berlin: Springer, 1989. 83-99.
28. Goidenberg D. M., Sharkey R. M., Paganelli G. et al. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J. Clin. Oncol. 2006;24:824-834.
29. Fiett T., Thiel e Antibody therapy in non-Hodgkin's lymphoma: the role of ritnximab, 90Y-ibritumomab tiuxetan, and alemtuzumab. Recent Results Cancer Res. 2007;176:153-163.
30. Ftnton C., Perry C. M. Cemtuzumab ozogamkin: a review of its use in acute myeloid leukaemia. BioDrugs 2006;20:137-139.
31. DeNardo G. L. Concepts in radwuninunomerapy and immunotherapy: Radioimmunotherapy from a Lym-1 perspective. Semin. Oncol. 2005;32:27-35.
32. Gutheil J. C., Campbell T. N., Pierce P. R. et al. Targeted antiangiogenic therapy for cancer using Vltaxin: a humanized monoclonal antibody to the integral α, β. Clin. Cancer Res. 2000;6:3056-3061.
33. Baselga J., Carbonett X., Castatteda-Soto N. J, et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J. Clin., Oncol. 2005;23:2162-2171.
34. Wu G., Borth R. F., Yang W. et al. Targeted delivery of methotrexate to epidermal growth factor receptor-positive brain tumors by means of cetuximab (IVC-C225) dendrimer bioconjugates. Mol. Cancer Ther. 2006;5:32-59.
35. Shih T., Lmdley C. Bevacizumab: an autogenesis inhibitor for the treatment of solid malignancies. Clin. Ther. 2006;28(11):1779-1802.
36. Sharkey R. M., Goldenberg D. M. Perspectives on cancer ther-. apy with radiolabeled monoclonal antibodies. J. Nucl. Med. 2005;46:115S-127S.
37. Dassand C. K., Choong P. F. M. Targeting of small molecule anticancer drugs to the tumour and its vasculature using cationic liposomes: lessons from gene therapy. Cancer Cell Int. 2006;6:17.
38. Slmberg D., Data T., Park J. H. et al. Biomimetk amplification of nanopartkle homing to tumors. Proc. Natl. Acad. Sci. USA 2007;104(3):932-936.
39. Hbto T, Yokota T, Ito Sh. In vivo delivery of small interfering RNA targeting brain capillary endothelial cells. Biochem. Biophysl. Res. Common. 2006;340:263-267.
40. Batchelor T. T, Sorensen A. G., Di Tomato e et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature an alleviates edema in glioblastoma patients. Cancer Cell 2007;11:83-95.
41. Brandsma D., van den Bent M. J. Molecular targeted therapies and chemotherapy in malignant gliomas. Curr. Opin. Oncol. 2007;19:598-605.
42. Day E. D., Lassiter S., Woodhatt A et al. The localization of radioantibodies in human brain tumors. I. Preliminary exploration. Cancer Res. 1965;25:773-778.
43. Goldenberg D. M., Deland P., Kim E. et al. Use of radiolabelled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning. N. Engl. J. Med. 1978;298:1384-1388.
44. 131I-labelled antitumor antibody. Radiology 1978;126:515-517.
45. Ooldenbrg D. M., Kim E. E., Deland F. H. et al. Human chorionic gonadotropin radioantibodies in the radioimmunodetection of cancer ami for discloser or occult metastases. Proc. Natl. Acad. Scl. USA 1981;78:7758-7784.
46. Axworthy D. B., Reno J. M., Hylarides M. D. et al. Cure of human carcinoma xenografts by a single dose of prctargeted yttrium-90 with negligible toxicity. Proc. Natl. Acad. Sci. USA 2000;97:1802-1807.
47. Paganelli G., Bartohmei M., Guana C. et a. Radioinimuno-therapy of brain tumor. Neurol. Res. 2006;28:518-522.
48. Reardon D. T., Means C. F., Goodwin D. A. et al. Antibodies against met al. chelates. Natiure 1985;316:265-268
49. Goodwin D. A., Means C. F., McCoil M. J. et al. Pre-targeted immunoscintigraphy of murine tumors with indium-111-tabeled bifunctional haptens. J. Nucl. Med. 1988;29:226-234.
50. Goodwln D. A., Meares C. F., Advances in pretangeting bicotechnology. Biotechnoi. Adv. 2001;19:435-450.
51. Boerman O. C., van Schaijk F. G., Oyen W. J. et al. Pretargeted radioimmunotherapy of cancer Progress step by step. J. Nucl. Med 2003;44:400-441.
52. Rossi E. A., Sharkey R. M., McBride W. et al. Development of new multivalent-bispecific agents for pretargeting tumor localization and therapy. Clin. Cancer Res. 2003;9:3886s-3896s.
53. Huhaiov A., Chester K. A. Engineered single chain antibody fragments for radioimmunotherapy. Quart. J. Nucl. Med. Mol. Imag. 2004;48:279-288.
54. Rossi E. A., Chang C.-H., Losman M. J. et al. Pretargeting of CEA-expressing cancer with a trivalent fusion protein produced in myeloma cells. Clin. Cancer Res. 2005;11:7122s-7129s.
55. Mamot C., Drummond D. C., Greiser U. et al. Epidermal Growth Factor Receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR-and EGFRvIII-overexpressing tumor cells. Cancer Res. 2003;63:3154-3161.
56. BignerS. H., Humphrey P. A., Wong A. J. et al. Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. Cancer Res. 1990;50:8017-8022.
57. Zhu Y., Parada L. F. The molecular and genetic basis of neurological tumors. Nat. Rev. Cancer 2002;2:616-626.
58. da Fonseca C. O., Landetro J. A., Clark S. S. et al. Recent advances in the molecular genetics of malignant gliomas disclose targets for antitumor agent perillyl alcohol. Surg. Neurol. 2006;65:S12-S19.
59. Zaheer A., Zhang W., Uc E. Y. et al. Expression of mRNAs of multiple growth factors and receptors by astrocytes and glioma cells: Detection with reverse transcription polymerase chain reaction. Cell Mol. Neurobiol. 1995;15:221-237.
60. Wang S. I., Puc J., Li J. et al. Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res. 1997;57:4183-4186.
61. Lu D., Zhang H., Koo H. et al. A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor fort enhanced antitumor activity. J. Biol. Chem. 2005;280(20):19665-19672.
62. Chaudhry I. H., O'Donovan D. G., Brenchley P. E. et al. Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas. Histopathology 2001;39:409-415.
63. Petrova T. V., Maklnen T, Alitalo K. Signaling via vascular endothelial growth factor receptors. Exp. Cell Res. 1999;253:117-130.
64. Cabebe E, Wokelee H. Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinas inhibitors. Curr. Treat. Options Oncol. 2007;8(1):15-27.
65. Scott L. J. Bevacizumab: in first-line treatment of metastatic breast cancer. Drugs 2007;67(12):1793-1799.
66. Ding H., Roncari L., Shannon P. et al. Astrocyte-specific expression of activated p21-ras results in malignant astrocytoma formation in a tranegenic mouse model of human gliomas. Cancer Res. 2001;61:3826-3836.
67. Bellacosa A., Kumar C. C., Di Cristofano A., Testa J. R. Activation of AKT kinases in cancer implications for therapeutic targeting. Adv. Cancer Res. 2005;94:29-86.
68. Sanson M., Lalgk-Donadey F., Benouakh-Amiel A. Molecular changes in brain tumors: prognostic and therapeutic impact. Curr. Opin. Oncol. 2006;18:623-630.
69. Jiang K., Coppola D., Cnspo N. C. et al. The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis. Mol. Cell. Biol. 2000;20:139-148.
70. Mizoguchi M., Nutt C. L., Mohapatra G., Louis D. N. Genetic alterations of phosphoinositide 3-kinase subunit genes in human glioblastomas. Brain Pathol. 2004;14:372-377.
71. Clark S. S., Zhong L., Filiaut D. et al. Anti-leukemia effect of perillyl alcohol in Bcr/Abl-transformed cells indirectly inhibits signaling through Mek in Ras-and Raf-independent fashion. Clin. Cancer Res. 2003;9:4494-4504.
72. Karp J. E, Kaufmarm S. H., Adjei A. A. et al. Current status of clinical trials of farnesyltransferase inhibitors. Curr. Opin. Oncol. 2001;3:470-476
73. Guha A., Feldkamp M. M., Lau N. et al. Proliferation of human malignant astrocytomas are dependent on Ras activation. Oncogen 1997;15:2755-2765.
74. Feldkamp M. M., Lau N., Roncari L., Guha A. Isotype-specific Ras. GTP-tevels predict the efficacy of temesyl transferase inhibitors against human astrocytomas regardless of Ras mutational status. Cancer Res. 2001;61:4425-4431.
75. Samenl M., Dosescu J., Shane B. F. Imaging proteolysis by Irving human glioma cells. Bol. Chem. 2001;382:785-788.
76. Demchik L., Sameni M., Nelson K. et al. Cathepsin B and glioma invasion. Int. J. Dev. Neurosci. 1999;17:483-494.
77. Grobben B., De Deyn P. P., Siegers H. Rat C6 glioma as experimental model system for the study of glioblastoma growth and invasion. Cell Tissue Res. 2002;310:257-270.
78. Leins A., Riva P., Lindstedt R. et al. Expression of tenascin-C in various human brain tumors and its relevance for survival in patients with atocytoma. Cancer 2003;98:2430-2439.
79. Herold-Mende C., Mueller M. M., Bonsanlo M. M. et al. Clinical impact an functional aspects of tenascin-C expression during glioma progression. Int J. Cancer 2002;98:362-369.
80. Zalutsky M. R. Current status of therapy of solid tumors: Brain tumor therapy. J. Nucl. Med. 2005;46(suppl.):151S-156S.
81. Zalutsky M. R., Pozzi O. R. Radioimmunotherapy with alphaparticle emitting radionuclides. Quart. J. Nucl. Med. Mol. Imag. 2004;48:289-296.
82. 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies. Cancer Res. 1989;49:2807-2813.
83. Bigner D. D., Brown M. T., Friedman A. H. et al. Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: Phase I trial results. J. Clin. Oncol. 1998;16:2202-2212.
84. Cokgor I., Akabani G., Kuan C.-T. et al. Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas. J. Clin. Oncol. 2000;18:3862-3871
85. Curran W. J., Scott C. B., Motion J. et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J. Natl. Cancer Inst. 1993;85:704-710.
86. 131 I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J. Clin. Oncol. 2002;20:1389-1391
87. Reardon D. A., Akabani G., Quinn J. A. et al. Novel human Ig2b/murine antitenascin monoclonal antibody construct radiolabeled with "'I and administered into the surgically created resection cavity of patients with malignant glioma: Phase I trial results. J. Nucl. Med. 2006;47:912-918.
88. Goetz C., Rtva P., Poepperl G. et al. Locoregional radioimmunotherapy in selected patients with malignant glioma: Experiences, side effects an survival times. J. Neurooncol. 2003:62:321-328.
89. Akabani G., McLendon R. E., Bigner D. D., Zalutsky M. R. Vascular targeted endoradiotherapy of tumors using alpha-particleemitting compounds: Theoretical analysis. Int. J. Radiat Oncol. Bol. Phys. 2002;4:1259-1275.
90. 90Y-biotin dosimetry and pharmacokinetics in cancer patients. Eur. J. Nucl. Med. 1999;26:110-120.
91. Paganelli G., Grana C., Chinol M. et al. Antibody-guided threestep therapy for high grade glioma with yttrium-90 biotin. Eur. J. Nucl. Med. 1999;26:348-357.
92. Paganelli G., Pervez S., Siccardi A. G. et al. Intraperitoneal radiolocalization of tumors pretargeted by biotinylated monoclonal antibodies. Int. J. Cancer 1990;45:1184-1189.
93. Sorial J.-C., Fayettel J., Armand J.-P. Molecular targeting: Targeting angiogenesis in solid tumors. Ann. Oncol. 2004;15(suppl. 4):iv223-iv227.
94. Reddy G. R., Bhojani M. S., McConville P. et al. Vascular targeted nanoparticle for imaging and treatment of brain tumors. Clin. Cancer Res. 2006;12:6677-6686.
95. Hnasko R., Frank P. G., Ben-Jonathan N., Lisanti M. P. PV-1 is negatively regulated by VEGF in the lung of caveolin-1, but not caveolin-2, null mice, Cell Cycle 2006;17:2012-2020.
96. Kallmann R., Mayer D. N., Berg E. L. et al. Novel mouse endothelial cell surface marker is suppressed during differentiation of the blood brain barrier. Dev. Dyn. 1995;202:325-332.
97. Carson-Walter E. B., Hampton J., Shue E. et al. Plasmalemmal vesicle associated protein-1 is a novel marker implicated in brain tumor angiogenesis. Clin. Cancer Res. 2005;11:7643-7650
98. Leenstra S., Troost D., Das P. K. et al. Endothelial cell marker PAL-E reactivity in brain tumor, developing brain, and brain disease, Cancer 1993;72:3061-3067.
99. Schlingemann R. O., Holman P., Vrensen G. F. et al. Increased expression of endothelial antigen PAL-E in human diabetic etionpathy correlates with microvascular leakage. Diabetologia 1999;42:596-602.
100. Wolburg H., Lippoldt A. Tight junctions of the blood-brain barrier Development, composition and regulatioin. Vase. Pharmacol. 2002;38:323-337.
101. Errede M., Benaglano V., Girolamo F. et al. Differential expression of connexin 43 in foet al., adult and tumour-associated human brain endothelial cells. Histochem. J. 2002;34:265-271.
102. Huang R., Lin Y, Wang C. C. et al. Connexin 43 suppresses human glioblastoma cell growth by down-regulation of monocyte chemotactic protein 1, as discovered using protein array technology. Cancer Res. 2002;62(10):2806-2812.
103. Lin J. H, Takano T., Cotrina M. L. et al. Connexin 43 enhances the adhesivity and mediates the invasion of malignant glioma cells. J. Neurosci. 2002;22(11):4302-4311.
104. 3 for angiogenesis. Science 1994;264:569-571.
105. Cai W., Chen X. Anti-angiogenic cancer therapy based on integrin alphavbeta3 antagonism. Anticancer Agents Med. Chem. 2006;6(5):407-428.
106. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994;79:1157-1164.
107. 3 Integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion. Clin. Cancer Res. 2005;11:7851-7860.
108. Chen S., Yu L., Jiang C. et al. Pivotal study of iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer. J. Clin. Oncol. 2005;23:1538-1547.
109. l31I-chimeric (ch) TNT-l/B monoclonal antibody for the treatment of advanced colon cancer. Cancer Biother. Radiopharm. 2006;21:243-256.
110. 131I-chTNT radioimmunotherapy of 43 patients with advanced lung cancer. Cancer Biother. Radiopharm. 2006;21:5-14.
111. Locher G. Biological effects and therapeutic possibilities of neutrons. Am. J. Roentgenol. 1936;36:1.
112. Barm R. F., Yang W., Adams D. M. et al. Molecular targeting of the epidermal growth factor receptor for neutron capture therapy of gliomas. Cancer Res. 2002;62:3159-3166.
113. Earth R. F., Soloway A. H., Goodman J. H. et al. Boron neutron capture therapy of brain tumors: An emerging therapeutic modality. Neurosurgery 1999;44:433-451.
114. Coderre J. A., Morris G. M. The radiation biology of bron ineutron capture therapy. Radiat. Res. 1999;151:1-18.
115. Soloway A. H., Tjarks W., Bamum B. A. et al. The chemistry of neutron capture therapy. Chem. Rev. 1998;98:1515-1562.
116. Barth R. F., Adams D. M., Soloway A. H. et al. Boronated starburst dendrimer-monoclonal antibody immunoconjugates: Evaluation as a potential delivery system for neutron capture therapy. Bioconjug. Chem. 1994;5:58-66.
117. Liu L., Barth R, F., Adams D. M. et al. Critical evaluation of bi-specific antibodies as targeting agents for boron neutron capture therapy of brain tumors. Anticancer Res. 1996;16:2581-2588.
118. Hoffman J. A., Giraudo E., Singh M. et al. Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma. Cancer Cell 2003;4:383-391.
119. Nieder C., Adam M., Molls M., Grosu A, L. Therapeutic options foir recurrent high-grade glioma in adult patients: Recent advances. Crit. Rev. Oncol. Hematol. 2006;60:181-193.
120. Bagshawe K. D., Sharma S. K., Begent R. H. Antibody-directed enzyme prodrug therapy (ADEPT) for cancer. Expert. Opin. Biol. Ther. 2004;4:1777-1789.
121. Miller C. R., Williams C. R., Buchsbaum D. J., Gillespie G. Y. Intratumoral 5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy is effective for experimental human glioblastomas. Cancer Res. 2002;62:773-780.